Muhunthan Thillai MD, co-founder and CEO, Qureight, commented: “Rebecca’s experience, expertise and people-centric leadership ...
Lundbeck A/S has announced encouraging new data from the intravenous part of its phase 2b PROCEED trial, showing that investigational migraine prevention treatment bocunebart achieved its primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results